U.S. Markets closed
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • Dow 30

    35,754.75
    +35.32 (+0.10%)
     
  • Nasdaq

    15,786.99
    +100.07 (+0.64%)
     
  • Russell 2000

    2,271.71
    +17.92 (+0.80%)
     
  • Crude Oil

    72.65
    +0.29 (+0.40%)
     
  • Gold

    1,784.60
    -0.90 (-0.05%)
     
  • Silver

    22.45
    +0.02 (+0.08%)
     
  • EUR/USD

    1.1346
    +0.0073 (+0.6467%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • Vix

    19.90
    -1.99 (-9.09%)
     
  • GBP/USD

    1.3207
    -0.0035 (-0.2668%)
     
  • USD/JPY

    113.7300
    +0.1900 (+0.1673%)
     
  • BTC-USD

    50,490.15
    -28.05 (-0.06%)
     
  • CMC Crypto 200

    1,320.56
    +15.44 (+1.18%)
     
  • FTSE 100

    7,337.05
    -2.85 (-0.04%)
     
  • Nikkei 225

    28,860.62
    +405.02 (+1.42%)
     

Recap: Halozyme Therapeutics Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Halozyme Therapeutics (NASDAQ:HALO) decreased in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 308.33% over the past year to $0.50, which missed the estimate of $0.53.

Revenue of $121,703,000 rose by 126.78% year over year, which beat the estimate of $120,160,000.

Outlook

Halozyme Sees FY21 Sales $375M-$395M Vs 400M Estimates, EPS $1.40-$1.55 Vs $1.7 Estimates

Details Of The Call

Date: Feb 23, 2021

Time: 04:30 PM

View more earnings on HALO

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.halozyme.com%2F&eventid=2947806&sessionid=1&key=147CF17EFD19E121D0254E970DB686F5&regTag=&V2=false&sourcepage=register

Recent Stock Performance

52-week high: $51.30

Company's 52-week low was at $12.71

Price action over last quarter: Up 42.28%

Company Overview

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.